NL-OMON39544已完成3 期
A double blind randomized placebo controlled study on the efficacy of intralymphatic immunotherapy in the treatment of grasspollen induced allergic rhinitis. - ILIT
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Sensibilisation to grass pollen
- •age between 18 and 50 years old
- •Informed consent
排除标准
- •No informed consent
- •instable or steroidtherapy dependent atopic astma
- •rhinosinusitis
- •nasal polyps
- •vasomotore rhinitis
- •immunosupressive medication
- •immuondeficiancy (IgG-IgA deficiaccy, HIV-AIDS)
- •pregnany or nursing
- •participation in other medical study
- •history of desensibilisation therapy
- •Significant cardiovascular disease
- •Severe impaired renal function
- •Hypersensitivity to aluminiumhydroxid
- •Childeren untill age of 18
- •Blood donation within previous 30 days
- •Surgery within the previous 30 days
- •Use of investigational drugs within previous 90 days
- •Mastocytosis
- •Hypertension
- •Active infectious disease
- •Significant hepatic disease
- •Significant renal disease
- •Significant hematological disorder
- •Significant pulmonary disease
- •Moderate or severe asthma
- •Autoimmune disease
- •History of malignancy.
- •Contraindicated medications were immunosuppressive agents, beta-blockers, ACE-inhibitors, and tricyclic antidepressants.
研究者
相似试验
撤回
2 期
A randomized double blind placebo controlled study on the effects of fenretinide Lym-X-Sorb on insulin sensitivity in obese insulin resistant subjectsobesitasimpaired glucose tolerance1001842410019654Insulin resistanceNL-OMON37344Academisch Medisch Centrum20
进行中（未招募）
1 期
SAR231893-LPS15497- Dupilumab effect on Sleep in AD patients”Atopic dermatitisEUCTR2018-004705-26-ESSanofi Aventis Groupe188
进行中（未招募）
1 期
SAR231893-LPS15497- Dupilumab effect on Sleep in AD patientsAtopic dermatitisEUCTR2018-004705-26-ITSANOFI-AVENTIS GROUPE188
进行中（未招募）
1 期
SAR231893-LPS15497- Dupilumab effect on Sleep in AD patients”MedDRA version: 20.0Level: PTClassification code 10012438Term: Dermatitis atopicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersAtopic dermatitisEUCTR2018-004705-26-FRSanofi Aventis Groupe268
进行中（未招募）
1 期
SAR231893-LPS15497- Dupilumab effect on Sleep in AD patients”Atopic dermatitisEUCTR2018-004705-26-DESanofi Aventis Groupe268